Show simple item record

dc.contributor.authorDewick, Laura
dc.contributor.authorAsher, Viren
dc.date.accessioned2018-06-11T10:26:31Z
dc.date.available2018-06-11T10:26:31Z
dc.date.issued2018
dc.identifier.citationEuropean Journal of Gynaecological Oncology; 2018; vol. 39 (no. 1); p. 49-52en
dc.identifier.urihttps://orda.derbyhospitals.nhs.uk/handle/123456789/1604
dc.descriptionCopyright Unclearen
dc.description.abstractPurpose of Investigation: The role of adjuvant chemotherapy in Stage 1 ovarian cancer is conflicting with no clear evidence to support adjuvant chemotherapy versus observation alone. The authors sought to establish the survival benefit of adjuvant chemotherapy in all Stage 1 ovarian cancers. Materials and Methods: Retrospective data including age, stage, grade, histology, RMI, and chemotherapy status on all patients undergoing treatment for Stage 1 ovarian cancer between May 2003 and November 2013 at Royal Derby Hospital was collected. Results: Eighty-nine cases of Stage 1 ovarian cancer were included. A total of 73 patients (84.88%) received adjuvant chemotherapy while 13 (15.12%) did not. The patients receiving adjuvant chemotherapy had a median overall survival (OS) of 108 months (CI 99.07-118.33) while the median OS for the patients who did not receive any adjuvant treatment was 63.71 months (CI 43.06-83.35) p = 0.003. Conclusion: Adjuvant chemotherapy significantly improves OS in Stage 1 ovarian cancer patients.en
dc.language.isoenen
dc.subjectAdjuvant Chemotherapyen
dc.subjectOvarian Canceren
dc.titleChemotherapy improves survival rate in Stage 1 ovarian cancersen
dc.typeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record